Guanhao Biotech

Guanhao Biotech Co., Ltd. (hereinafter referred to as "Guanhao Biotech"), the predecessor of the company was established in California, USA in 1997, returned to China for entrepreneurship in 1999, and was listed on the ChiNext board of the Shenzhen Stock Exchange in 2011, with stock code 300238.
Guanhao Biotech is a high-tech enterprise based in the regenerative medicine industry, expanding into life and health related fields, integrating global high-end technology resources and achievements, and continuously laying out in biomaterials, cell and stem cells, pharmaceuticals, as well as advanced medical technology and product business fields. After more than ten years of development, the core business has formed a "3+1" pattern, namely materials, cells, pharmaceuticals + technology incubation, with specific businesses covering multiple medical departments such as neurosurgery, ophthalmology, and dermatology.
In the field of regenerative materials, after more than ten years of development, the animal-derived biomaterial technology platform built by the company is a technology platform with international competitiveness. Relying on its leading level in the research and development of new biomaterials with induced regeneration function and their products, Guanhao Biotech undertakes more than twenty national and local scientific and technological projects. The "National Engineering Laboratory for Regenerative Medical Implant Devices" and the "High-tech Industrialization Demonstration Project for Regenerative Biofilm" initiated by the National Development and Reform Commission have successively been settled at Guanhao Biotech. Currently, the company has more than one hundred domestic and foreign patents. The main products on the market include biological dural (spinal) membrane patch, B-type dural patch, thoracic and general surgery repair membrane, sterile biological wound protective film, Aireo breast patch, and Youdeqing acellular corneal implant. Among them, the biological dural (spinal) membrane patch quickly occupied the domestic dural patch market with excellent performance after its launch, completely replacing imported products from Johnson & Johnson and B. Braun, and now ranks among the top in domestic market share; Youdeqing acellular corneal implant adopts a world-first technology, is a product with blindness reversal and vision restoration as the main therapeutic indicators, bringing light to many blind patients. This product and technology have recently been featured in special reports by CCTV's Focus Report and Guangdong TV.
In the field of cell and stem cells, the company is currently involved in autologous chondrocyte tissue transplantation technology and immune cell storage technology, and is continuously laying out in the research and development of immune cell therapy technology. The company cooperates with Peking University and Professor Deng Hongkui's team to establish the Beihao Stem Cell and Regenerative Medicine Research Institute, which will build a common key technology platform for immune cells, gather a group of global advanced talents and technologies, and carry out stem cell and clinical transformation research.
In the pharmaceutical field, the company holds 58.20% equity of Beijing Wenfeng, which owns the intellectual property rights of the Class 1.1 new drug Benvitimod in Greater China. Benvitimod is a non-hormonal small molecule compound isolated from natural microbial metabolites. This drug is the world's first and can be used to treat various autoimmune diseases, such as psoriasis (commonly known as "psoriasis") and eczema, and has been listed by the Ministry of Science and Technology as a major special project for "Significant New Drug Creation" during the "Twelfth Five-Year Plan" period.
In the field of technology incubation, Guanhao Technology Incubation business will operate through a "park + fund" model, integrating global high-end technology research and development resources and achievements, conducting innovative incubation for the Chinese market, focusing on the regenerative medicine industry for early-stage project incubation, forming strong support for materials, cells, and pharmaceutical businesses.
In the future, the company will continue to center around the regenerative medicine biomaterial platform and cell therapy technology platform, integrate resources along the regenerative medicine field, increase the intensity of industrialization transformation, and build Guanhao Biotech into a first-class provider of products, technologies, and services in the regenerative medicine industry.